Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
AssigneeBoard of Regents, The University of Texas System
InventorsPhilip E. Thorpe, M. Melina Soares, Sophia Ran
Life of this patent
Estimating the term…
Abstract
Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.
Claims205
An immunoconjugate comprising monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, operatively attached to one or more anti-viral agents.
A composition comprising a biologically effective amount of an immunoconjugate that comprises one or more anti-viral agents operatively attached to monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an immunoconjugate that comprises one or more anti-viral agents operatively attached to monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof.
An immunoconjugate comprising an antibody, or antigen-binding fragment thereof, operatively attached to one or more anti-viral agents;
- wherein said antibody, or antigen-binding fragment thereof, comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A composition comprising an immunoconjugate that comprises one or more anti-viral agents operatively attached to an antibody, or antigen-binding fragment thereof;
- wherein said antibody, or antigen-binding fragment thereof, comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an immunoconjugate that comprises one or more anti-viral agents operatively attached to an antibody, or antigen-binding fragment thereof;
- wherein said antibody, or antigen-binding fragment thereof, comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A composition comprising a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- and at least a second anti-viral agent;
- wherein said antibody, or antigen-binding fragment thereof, is monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or antigen-binding fragment thereof.
A pharmaceutical composition comprising a therapeutically effective amount of a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- in combination with a therapeutically effective amount of at least a second anti-viral agent;
- wherein said antibody, or antigen-binding fragment thereof, is monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or antigen-binding fragment thereof.
A kit comprising, in at least a first container, at least a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- and at least a second anti-viral agent;
- wherein said antibody, or antigen-binding fragment thereof, is monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or antigen-binding fragment thereof.
A composition comprising a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- and at least a second anti-viral agent;
- wherein said antibody, or antigen-binding fragment thereof, comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A pharmaceutical composition comprising a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti- viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- in combination with at least a second anti-viral agent;
- wherein said antibody, or antigen-binding fragment thereof, comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A kit comprising, in at least a first container, at least a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- and at least a second anti-viral agent;
- wherein said antibody, or antigen-binding fragment thereof, comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
An immunoconjugate comprising an antibody, or antigen-binding fragment thereof, operatively attached to one or more anti-viral agents;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A composition comprising an immunoconjugate that comprises one or more anti-viral agents operatively attached to an antibody, or antigen-binding fragment thereof;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A composition comprising a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof and at least a second anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A kit comprising, in at least a first container, at least a first anti-viral agent, wherein said first anti-viral agent is an anti-viral immunoconjugate comprising one or more anti-viral drugs operatively attached to an antibody, or antigen-binding fragment thereof;
- and at least a second anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a mammalian cell with an immunoconjugate that comprises at least a first anti-viral agent operatively attached to monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, in an amount effective to inhibit virus replication in said cell or inhibit spread to additional host cells or tissues from said cell.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a population of mammalian cells with an immunoconjugate that comprises at least a first anti-viral agent operatively attached to monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, in an amount effective to inhibit virus replication in said population of cells or inhibit spread to additional host cells or tissues from said population of cells.
A method for treating a mammal with a viral infection, comprising administering to said mammal a pharmaceutical composition comprising an immunoconjugate that comprises at least a first anti-viral agent operatively attached to monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, in an amount effective to inhibit viral replication or spread in said mammal, thereby treating said viral infection.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a mammalian cell with an immunoconjugate that comprises at least a first anti-viral agent operatively attached to an antibody, or an antigen- binding fragment thereof, in an amount effective to inhibit virus replication in said cell or inhibit spread to additional host cells or tissues from said cell;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A method for treating a mammal with a viral infection, comprising administering to said mammal a pharmaceutical composition comprising an immunoconjugate that comprises at least a first anti-viral agent operatively attached to an antibody, or an antigen-binding fragment thereof, in an amount effective to inhibit viral replication or spread in said mammal, thereby treating said viral infection;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a mammalian cell with an immunoconjugate that comprises at least a first anti-viral agent operatively attached to an antibody, or an antigen- binding fragment thereof, in an amount effective to inhibit virus replication in said cell or inhibit spread to additional host cells or tissues from said cell;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A method for treating a mammal with a viral infection, comprising administering to said mammal a pharmaceutical composition comprising an immunoconjugate that comprises at least a first anti-viral agent operatively attached to an antibody, or an antigen-binding fragment thereof, in an amount effective to inhibit viral replication or spread in said mammal, thereby treating said viral infection;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A composition comprising a first anti-viral agent, wherein said first anti-viral agent is monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent.
A pharmaceutical composition comprising a first anti-viral agent, wherein said first anti-viral agent is monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent.
A kit comprising, in at least a first container, at least a first anti-viral agent, wherein said first anti-viral agent is monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent.
A composition comprising a first anti-viral agent, wherein said first anti-viral agent is an antibody, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A kit comprising, in at least a first container, at least a first anti-viral agent, wherein said first anti-viral agent is an antibody, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A pharmaceutical composition comprising a first anti-viral agent, wherein said first anti-viral agent is an antibody, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A composition comprising a first anti-viral agent, wherein said first anti-viral agent is an antibody, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A pharmaceutical composition comprising a first anti-viral agent, wherein said first anti-viral agent is an antibody, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A kit comprising, in at least a first container, at least a first anti-viral agent, wherein said first anti-viral agent is an antibody, or an antigen-binding fragment thereof;
- and at least a second, distinct anti-viral agent;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a mammalian cell with monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, in an amount effective to inhibit virus replication in said cell or inhibit spread to additional host cells or tissues from said cell.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a population of mammalian cells with monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, in an amount effective to inhibit virus replication in said population of cells or inhibit spread to additional host cells or tissues from said population of cells.
A method for treating a mammal with a viral infection, comprising administering to said mammal a pharmaceutical composition comprising monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof, in an amount effective to inhibit viral replication or spread in said mammal, thereby treating said viral infection.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a mammalian cell with an antibody, or an antigen-binding fragment thereof, in an amount effective to inhibit virus replication in said cell or inhibit spread to additional host cells or tissues from said cell;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A method for treating a mammal with a viral infection, comprising administering to said mammal a pharmaceutical composition comprising an antibody, or an antigen-binding fragment thereof, in an amount effective to inhibit viral replication or spread in said mammal, thereby treating said viral infection;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:
- (a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12;
- and
- (b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.
A method of inhibiting virus replication or spread to additional host cells or tissues, comprising contacting a mammalian cell with an antibody, or an antigen-binding fragment thereof, in an amount effective to inhibit virus replication in said cell or inhibit spread to additional host cells or tissues from said cell;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
A method for treating a mammal with a viral infection, comprising administering to said mammal a pharmaceutical composition comprising an antibody, or an antigen-binding fragment thereof, in an amount effective to inhibit viral replication or spread in said mammal, thereby treating said viral infection;
- wherein said antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:
- (a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2;
- or
- (b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.
Dependencies are inferred from the claim text.